Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.

Muñoz-Pinedo C, González-Suárez E, Portela A, Gentilella A, Esteller M.

Cancer Res. 2013 Jul 15;73(14):4185-9. doi: 10.1158/0008-5472.CAN-13-0512. Epub 2013 May 17.

2.

The evolution of the TOR pathway and its role in cancer.

Beauchamp EM, Platanias LC.

Oncogene. 2013 Aug 22;32(34):3923-32. doi: 10.1038/onc.2012.567. Epub 2012 Dec 17. Review.

PMID:
23246968
3.

Targeting PI3K/mTOR signaling in cancer.

Emerling BM, Akcakanat A.

Cancer Res. 2011 Dec 15;71(24):7351-9. doi: 10.1158/0008-5472.CAN-11-1699. Epub 2011 Oct 10.

4.

Circumventing cancer drug resistance in the era of personalized medicine.

Garraway LA, Jänne PA.

Cancer Discov. 2012 Mar;2(3):214-26. doi: 10.1158/2159-8290.CD-12-0012. Epub 2012 Feb 28. Review.

5.

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart MJ.

Cancer Treat Rev. 2013 Dec;39(8):935-46. doi: 10.1016/j.ctrv.2013.03.009. Epub 2013 May 3.

PMID:
23643661
6.

German-Catalan workshop on epigenetics and cancer.

Vizoso M, Esteller M.

Epigenetics. 2013 Sep;8(9):998-1003. doi: 10.4161/epi.25856. Epub 2013 Jul 24.

7.

First Barcelona Conference on Epigenetics and Cancer.

Palau A, Perucho M, Esteller M, Buschbeck M.

Epigenetics. 2014 Mar;9(3):468-75. doi: 10.4161/epi.27759. Epub 2014 Jan 10.

8.

Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer.

Beckman RA, Schemmann GS, Yeang CH.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14586-91. doi: 10.1073/pnas.1203559109. Epub 2012 Aug 13.

9.

The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics.

Cloonan N, Waddell N, Grimmond SM.

IDrugs. 2010 Nov;13(11):778-81. Review.

PMID:
21046525
10.

The era of cancer discovery.

Cantley LC, Baselga J.

Cancer Discov. 2011 Jun;1(1):1. doi: 10.1158/2159-8274.CD-11-0049. Epub 2011 Jun 1. No abstract available.

11.

Cancer biomarkers: selecting the right drug for the right patient.

Kelloff GJ, Sigman CC.

Nat Rev Drug Discov. 2012 Feb 10;11(3):201-14. doi: 10.1038/nrd3651. Review.

PMID:
22322254
12.

The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.

Soliman GA.

Nutrients. 2013 Jun 19;5(6):2231-57. doi: 10.3390/nu5062231. Review.

13.

Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives.

Metzger-Filho O, Moulin C, Awada A.

Curr Clin Pharmacol. 2010 Aug;5(3):166-77. Review.

PMID:
20406173
14.

The promise of mTOR inhibitors in the treatment of colorectal cancer.

Kim DD, Eng C.

Expert Opin Investig Drugs. 2012 Dec;21(12):1775-88. doi: 10.1517/13543784.2012.721353. Epub 2012 Sep 16. Review.

PMID:
22978346
15.

[mTOR inhibitor].

Muro K.

Gan To Kagaku Ryoho. 2011 Jan;38(1):7-11. Japanese.

PMID:
21368454
16.

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.

Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E, Faivre S.

Target Oncol. 2011 Jun;6(2):119-24. doi: 10.1007/s11523-011-0177-6. Epub 2011 Apr 28. Review.

PMID:
21533544
17.

New frontiers in therapeutic resistance in cancer.

Sartore-Bianchi A, Delorenzi M, Gagnon-Kugler T, Rousseau C, Batist G.

Expert Rev Anticancer Ther. 2012 Jul;12(7):877-9. doi: 10.1586/era.12.71.

PMID:
22845402
18.

The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.

Ibáñez E, Agliano A, Prior C, Nguewa P, Redrado M, González-Zubeldia I, Plano D, Palop JA, Sanmartín C, Calvo A.

Curr Med Chem. 2012;19(18):3031-43.

PMID:
22455594
19.

mTOR inhibitors: facing new challenges ahead.

Mavrommati I, Maffucci T.

Curr Med Chem. 2011;18(18):2743-62. Review.

PMID:
21649581
20.

Biomarker-driven patient selection for early clinical trials.

Dienstmann R, Rodon J, Tabernero J.

Curr Opin Oncol. 2013 May;25(3):305-12. doi: 10.1097/CCO.0b013e32835ff3cb. Review.

PMID:
23493192
Items per page

Supplemental Content

Write to the Help Desk